CL2024002725A1 - Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo - Google Patents
Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmoInfo
- Publication number
- CL2024002725A1 CL2024002725A1 CL2024002725A CL2024002725A CL2024002725A1 CL 2024002725 A1 CL2024002725 A1 CL 2024002725A1 CL 2024002725 A CL2024002725 A CL 2024002725A CL 2024002725 A CL2024002725 A CL 2024002725A CL 2024002725 A1 CL2024002725 A1 CL 2024002725A1
- Authority
- CL
- Chile
- Prior art keywords
- nmo
- aqp4
- aquaporin
- novel treatment
- mhc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164161.6A EP4249062A1 (en) | 2022-03-24 | 2022-03-24 | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002725A1 true CL2024002725A1 (es) | 2025-02-14 |
Family
ID=81325683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002725A CL2024002725A1 (es) | 2022-03-24 | 2024-09-11 | Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250205322A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4249062A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025510786A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240164796A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119110810A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023237632A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250911A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002725A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024012332A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314754A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011666A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023180549A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025061917A1 (en) * | 2023-09-22 | 2025-03-27 | Julius-Maximilians-Universität Würzburg | Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9234017B2 (en) * | 2012-12-11 | 2016-01-12 | The Regents Of The University Of California | Aquaporin-4 peptide compositions and methods of use thereof |
| SG11201909290TA (en) * | 2017-04-07 | 2019-11-28 | Uti Lp | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
| CA3063959A1 (en) | 2017-05-23 | 2018-11-29 | Julius-Maximilians-Universitat Wurzburg | Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation |
| WO2021184017A1 (en) * | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
-
2022
- 2022-03-24 EP EP22164161.6A patent/EP4249062A1/en not_active Withdrawn
-
2023
- 2023-03-24 CN CN202380029744.3A patent/CN119110810A/zh active Pending
- 2023-03-24 EP EP23716418.1A patent/EP4499231A1/en active Pending
- 2023-03-24 CA CA3250911A patent/CA3250911A1/en active Pending
- 2023-03-24 WO PCT/EP2023/057684 patent/WO2023180549A1/en not_active Ceased
- 2023-03-24 KR KR1020247034451A patent/KR20240164796A/ko active Pending
- 2023-03-24 IL IL314754A patent/IL314754A/en unknown
- 2023-03-24 MX MX2024011666A patent/MX2024011666A/es unknown
- 2023-03-24 JP JP2024556458A patent/JP2025510786A/ja active Pending
- 2023-03-24 US US18/849,075 patent/US20250205322A1/en active Pending
- 2023-03-24 AU AU2023237632A patent/AU2023237632A1/en active Pending
-
2024
- 2024-09-11 CO CONC2024/0012332A patent/CO2024012332A2/es unknown
- 2024-09-11 CL CL2024002725A patent/CL2024002725A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024012332A2 (es) | 2024-09-30 |
| CA3250911A1 (en) | 2023-09-28 |
| US20250205322A1 (en) | 2025-06-26 |
| EP4249062A1 (en) | 2023-09-27 |
| KR20240164796A (ko) | 2024-11-20 |
| WO2023180549A1 (en) | 2023-09-28 |
| MX2024011666A (es) | 2024-09-27 |
| AU2023237632A1 (en) | 2024-08-15 |
| CN119110810A (zh) | 2024-12-10 |
| EP4499231A1 (en) | 2025-02-05 |
| IL314754A (en) | 2024-10-01 |
| JP2025510786A (ja) | 2025-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001278A1 (es) | Vesículas extracelulares modificadas y sus usos | |
| CY1123315T1 (el) | Απο-ανοσοποιημενα, ικριωματα υπομοναλων α τοξινων shiga και μορια στοχευσης-κυτταρων περιλαμβανοντας τα ιδια | |
| CR20180492A (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
| MX2023002181A (es) | Anticuerpos anti-ror1 y proteinas de union biespecificas relacionadas. | |
| CO2025000513A2 (es) | Anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1, composiciones que comprenden anticuerpos anti-ror1 o conjugados de anticuerpos anti-ror1 y métodos para hacer y usar anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1 | |
| PE20190436A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 | |
| CO2024012332A2 (es) | Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo | |
| PE20121636A1 (es) | Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas | |
| CL2024001738A1 (es) | Vacunas peptídicas | |
| CL2021002459A1 (es) | Péptidos y combinaciones de péptidos para uso en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) | |
| BR112022017032A2 (pt) | Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas. | |
| UY38200A (es) | Conjugados de tirosina-tirosina de péptido cíclico acoplado a péptido de fusión de glp-1 y sus usos | |
| AR115721A1 (es) | Anticuerpos que comprenden un polipéptido insertado en la región marco 3 | |
| AR122659A1 (es) | Anticuerpos biespecíficos para linfocitos t activados por proteasa | |
| CL2022003205A1 (es) | Cisteína proteasa | |
| CO2025009946A2 (es) | Proteínas de unión al antígeno anti-tnfr2 y sus usos | |
| CL2023000326A1 (es) | Péptidos y sus combinaciones para su uso en inmunoterapia contra una infección por sars-cov-2 (covid-19) | |
| CL2024002724A1 (es) | Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson | |
| CO2024003578A2 (es) | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos | |
| CO2024013220A2 (es) | Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog | |
| CO2026004947A2 (es) | Proteínas de unión al receptor de transferrina y usos de estas | |
| CO2025011125A2 (es) | Conjugados anticuerpo-fármaco anti-cd70 | |
| CO2024012945A2 (es) | Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1 | |
| PE20250119A1 (es) | Peptidos y metodos para el tratamiento de neuromielitis optica | |
| CO2025008076A2 (es) | Proteínas de fusión fc de il-12 |